Recherche
-
Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination
(International Journal of Infectious Diseases. vol. 74, pp. 83-96, 2018-09)Article de revueLibre accès -
A randomized placebo-controlled efficacy study of a prime boost therapeutic vaccination strategy in HIV-1 infected individuals: VRI02 ANRS 149 LIGHT Phase II trial
(Journal of Virology, 2021-02-10)Article de revueLibre accès -
T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial
(Journal of Immunology. vol. 208, n° 12, pp. 2663-2674, 2022-06-15)Article de revue -
ChatGPT and beyond with artificial intelligence (AI) in health: Lessons to be learned.
(Joint Bone Spine. vol. 90, n° 5, pp. 105607, 2023-09-01)Article de revue -
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo
(Cell Reports. vol. 42, n° 9, pp. 113101, 2023-09-26)Article de revueLibre accès -
Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
(Frontiers in Immunology. vol. 10, 2019-04-24)Article de revueLibre accès -
Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions
(The Lancet HIV. vol. 6, n° 5, pp. e334-e340, 2019-05)Article de revueLibre accès -
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).
(Clinical Microbiology and Infection. vol. 28, n° 7, pp. 1010-1016, 2022-07-01)Article de revueLibre accès